Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
| ▸ | PTPRF | P10586 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515090 | 0.84 | ROCK2 (0.40) | ROCK2 | |
| SCHEMBL5680285 | 0.81 | PTPN1 (0.33) | PTPRCPTPRFPTPN1CDC25B | |
| SCHEMBL31633552 | 0.81 | PTPRC (0.30) | PTPRCPTPRFPTPN1CDC25B | |
| SCHEMBL19206292 | 0.80 | ROCK2 (0.45) | ROCK2EPHX2PTPRCPTPRFPTPN1 | |
| SCHEMBL25192884 | 0.77 | ROCK2 (0.39) | ROCK2 | |
| SCHEMBL30587348 | 0.76 | PTPRC (0.32) | PTPRCPTPRFPTPN1CDC25B | |
| SCHEMBL29626171 | 0.76 | FABP3 (0.35) | ROCK2 | |
| SCHEMBL648482 | 0.75 | BCHE (0.37) | PTPRCPTPRFPTPN1CDC25B | |
| SCHEMBL25202551 | 0.75 | ROCK2 (0.55) | ROCK2EPHX2 | |
| SCHEMBL14663496 | 0.74 | ROCK2 (0.41) | ROCK2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | disclosed |
| CN-111788206-B | Compound and polymer compound containing the same | 国立研究开发法人科学技术振兴机构 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11773070-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-03 | — | — | US | disclosed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | disclosed |
| CN-112300127-B | Organic compound, organic light emitting diode and organic light emitting display device including the same | 乐金显示有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | disclosed |
| EP-4114184-A1 | FUNGICIDAL COMPOSITIONS | Syngenta Crop Protection AG (CH) | 2023-01-11 | — | — | EP | disclosed |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-15 | — | — | US | disclosed |
| US-11427553-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-30 | — | — | US | disclosed |
| CN-102869667-A | Tricyclic pyridine derivatives, medicaments containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INT | 2013-01-09 | — | — | CN | disclosed |
| EP-2536733-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | Boehringer Ingelheim International GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| WO-2012110599-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | WO | disclosed |
| EP-2445886-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2445900-A2 | POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120053197-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| WO-2011101424-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773070-B2 | Dihydrooxadiazinones | CCND2, DPYD, DHPS | ROCK2 987/4885EPHX2 578/4885PTPRC 3362/4885 |
| US-20220396554-A1 | DIHYDROOXADIAZINONES | CCND2, DPYD, DHPS | ROCK2 987/4885EPHX2 578/4885PTPRC 3362/4885 |
| US-12258323-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | ROCK2 757/4885EPHX2 716/4885PTPRC 3384/4885 |
| US-20120053197-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | CETP, MTTP, CES1 | ROCK2 3723/4885EPHX2 1946/4885PTPRC 1173/4885 |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | ROCK2 757/4885EPHX2 716/4885PTPRC 3384/4885 |
| US-20120046304-A1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | CETP, MTTP, CES1 | ROCK2 3723/4885EPHX2 1946/4885PTPRC 1173/4885 |
| US-11427553-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | ROCK2 757/4885EPHX2 716/4885PTPRC 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.